Barclays PLC Crispr Therapeutics Ag Put Options Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $6.75 Million - $9.92 Million	-111,300 Reduced 73.22%	40,700 $2.77 Million
Q4 2023 Feb 15, 2024	BUY	$38.62 - $72.18 $5.87 Million - $11 Million	152,000 New	152,000 $9.52 Million
Q1 2023 May 04, 2023	BUY	$41.0 - $56.12 $1.37 Million - $1.87 Million	33,400 Added 50.15%	100,000 $4.52 Million
Q4 2022 Feb 13, 2023	BUY	$39.19 - $65.67 $2.61 Million - $4.37 Million	66,600 New	66,600 $2.71 Million
Q4 2020 Feb 11, 2021	SELL	$79.67 - $173.23 $4.54 Million - $9.87 Million	-57,000 Reduced 95.8%	2,500 $383,000
Q2 2018 Aug 14, 2018	BUY	$42.62 - $73.59 $1.59 Million - $2.74 Million	37,300 Added 168.02%	59,500 $3.5 Million
Q1 2018 May 15, 2018	BUY	$23.52 - $58.17 $522,144 - $1.29 Million	22,200 New	22,200 $1.02 Million

499

56.8M

1.7M

1.8M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.05B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.